Genomma Lab Internacional, S.A.B. de C.V. GNMLF
OTC PK
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -46.77% | -- | 10.51% | -5.56% | 81.77% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -46.77% | -- | 10.51% | -5.56% | 81.77% |
| Cost of Revenue | -43.46% | -- | 8.68% | -0.25% | 84.71% |
| Gross Profit | -48.66% | -- | 11.59% | -8.68% | 80.13% |
| SG&A Expenses | -47.21% | -- | 14.70% | -13.34% | 83.12% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 91.04% | -- | -43.94% | 593.71% | -436.04% |
| Total Operating Expenses | -44.92% | -- | 11.83% | -5.35% | 82.35% |
| Operating Income | -53.36% | -- | 5.77% | -6.41% | 79.73% |
| Income Before Tax | -35.19% | -- | 6.74% | 15.59% | 26.80% |
| Income Tax Expenses | -46.99% | -- | -14.22% | 54.41% | 40.00% |
| Earnings from Continuing Operations | -29.58% | -- | 15.25% | -2.58% | 21.36% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -29.58% | -- | 15.25% | 309.65% | 21.36% |
| EBIT | -53.36% | -- | 5.77% | -6.41% | 79.73% |
| EBITDA | -50.86% | 1,079.65% | 6.03% | -7.29% | 74.61% |
| EPS Basic | -71.37% | 22.35% | 16.00% | 311.63% | 91.62% |
| Normalized Basic EPS | -73.70% | -- | 7.76% | 19.76% | 100.00% |
| EPS Diluted | -71.37% | 22.35% | 16.00% | 311.63% | 91.62% |
| Normalized Diluted EPS | -73.70% | -- | 7.76% | 19.76% | 100.00% |
| Average Basic Shares Outstanding | 146.13% | -2.83% | -0.82% | -0.84% | -36.61% |
| Average Diluted Shares Outstanding | 146.13% | -2.83% | -0.82% | -0.84% | -36.61% |
| Dividend Per Share | -- | 11.65% | 16.33% | -72.68% | -- |
| Payout Ratio | -0.24% | -- | 0.01% | 1.56% | 0.67% |